Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-24 5:44 pm Sale | 2025-07-22 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 132,473 4.250% | -111,405 (-45.68%) | Filing History |
| 2025-07-21 5:28 pm Sale | 2025-07-17 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 243,878 7.820% | -52,299 (-17.66%) | Filing History |
| 2025-07-09 8:06 pm Sale | 2025-07-07 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 296,177 9.500% | -36,323 (-10.92%) | Filing History |
| 2025-04-25 7:48 pm Sale | 2025-04-22 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 332,500 10.700% | -37,743 (-10.19%) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 462,848 15.000% | 41,500 (+9.85%) | Filing History |
| 2024-12-26 4:31 pm Sale | 2024-12-20 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 370,243 12.000% | -31,457 (-7.83%) | Filing History |
| 2024-11-14 5:21 pm Sale | 2024-03-31 | 13G | Passage Bio, Inc. PASG | Erste Asset Management GmbH | 122,790 4.420% | -25,250 (-17.06%) | Filing History |
| 2024-11-14 5:01 pm Purchase | 2023-12-31 | 13G | Passage Bio, Inc. PASG | Erste Asset Management GmbH | 148,040 5.400% | 148,040 (New Position) | Filing History |
| 2024-11-14 12:03 pm Purchase | 2024-09-30 | 13G | Passage Bio, Inc. PASG | Vestal Point Capital, LP | 305,000 9.900% | 305,000 (New Position) | Filing History |
| 2024-08-09 7:06 pm Sale | 2024-08-07 | 13D | Passage Bio, Inc. PASG | Versant Venture Capital VI L.P. | 0 0.000% | -201,321 (Position Closed) | Filing History |
| 2024-08-09 5:15 pm Purchase | 2024-08-07 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 421,348 13.600% | 179,054 (+73.90%) | Filing History |
| 2024-05-29 4:35 pm Unchanged | 2024-05-24 | 13D | Passage Bio, Inc. PASG | Versant Venture Capital VI L.P. | 201,321 6.500% | 0 (Unchanged) | Filing History |
| 2024-04-12 5:35 pm Unchanged | 2024-04-09 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 401,700 13.000% | 0 (Unchanged) | Filing History |
| 2024-03-29 4:15 pm Purchase | 2024-03-19 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 242,294 8.700% | 223,336 (+1178.06%) | Filing History |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 18,958 0.700% | -148,838 (-88.70%) | Filing History |
| 2023-11-09 5:27 pm Unchanged | 2023-08-07 | 13D | Passage Bio, Inc. PASG | Versant Venture Capital VI L.P. | 201,321 7.300% | 0 (Unchanged) | Filing History |
| 2023-06-29 4:36 pm Purchase | 2023-06-27 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 401,700 14.700% | 59,629 (+17.43%) | Filing History |
| 2023-06-15 10:25 am Sale | 2023-06-13 | 13D | Passage Bio, Inc. PASG | Frazier Life Sciences IX, L.P. | 127,185 4.700% | -60,661 (-32.29%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 167,796 6.200% | 30,175 (+21.93%) | Filing History |
| 2023-02-14 08:53 am Sale | 2022-12-31 | 13G | Passage Bio, Inc. PASG | Deep Track Capital, LP | 0 0.000% | -160,850 (Position Closed) | Filing History |